[Self-evaluation of single test doses and objective indices of ladasten vs. placebo efficacy in neurasthenic patients].

Study findings

Patients with neurasthenia rated single-dose Ladasten tolerability similarly to placebo. The authors examined associations between self-ratings, baseline characteristics and subsequent treatment response.

Population and setting

Patients; see abstract scope

Evidence type

Human comparative study

Preparation

See the original report; formulation details require verification.

Source language

rus

Title source

Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

Study limitations

• Original full text and detailed methods have not been reviewed.
• Sample size, allocation, masking and numerical outcomes require full-text appraisal; the report cannot establish effects in healthy users.
• Possible overlap with other Ladasten neurasthenia reports, including the existing clinical program, remains unresolved; do not count this as independent replication.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Source access and review scope

Indexed citation and English abstract checked.

Recorded source-check date: 2026-10-07. This date does not imply a completed systematic review.

Open original source or index record ↗

Citation and original source

Original source: Reutova MA, Siuniakov SA, Siuniakov TS, Dorofeeva OA, Mametova LÉ, Neznamov GG. [Self-evaluation of single test doses and objective indices of ladasten vs. placebo efficacy in neurasthenic patients]. Eksperimental'naia i klinicheskaia farmakologiia; 2011 2011.

Molekul research summary: https://molekul.io/research/brom-extra-22288153. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Related compound profiles